High Tower Advisors, LLC Exelixis, Inc. Call Options Transaction History

High Tower Advisors, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2020 May 21, 2020	SELL	$14.46 - $21.8 $1,446 - $2,180	-100 Reduced 33.33%	200 $0
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $237,160 - $299,596	-12,100 Reduced 97.58%	300 $0
Q3 2018 Nov 09, 2018	SELL	$15.87 - $22.4 $144,417 - $203,840	-9,100 Reduced 42.33%	12,400 $2,000
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $189,312 - $228,990	10,200 Added 90.27%	21,500 $6,000
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $4,430 - $6,378	-200 Reduced 1.74%	11,300 $6,000
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $9,692 - $12,372	400 Added 3.6%	11,500 $15,000
Q3 2017 Nov 14, 2017	SELL	$23.35 - $29.24 $11,675 - $14,620	-500 Reduced 4.31%	11,100 $10,000
Q2 2017 Aug 14, 2017	BUY	N/A	11,600	11,600 $16,000

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.